Startups
Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.
Proniras Corporation launched from Accelerator Life Science Partners to treat nerve agents. The company recently received a contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) for $89.5 million.
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.
With $37 million in its pocket a new player has emerged to develop treatments for rare diseases.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash.
About two years ago, former president and chief executive officer of Sarepta Therapeutics, Chris Garabedian, formed Xontogeny, a biotech accelerator. Xontogeny was founded to support life science technology startups.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
The use of artificial intelligence and machine learning in drug development has been ramping up and investors are taking keen notice of the growing trend. This morning BenevolentAI snagged $115 million.
PRESS RELEASES